HemoCue America, a global leader in advanced point-of-care testing (POCT) systems, announced on October 9, 2013 that the American Red Cross, the world’s largest blood bank organization, has signed a five-year agreement on instruments and consumables for hemoglobin testing of blood donors.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63473-hemocue-red-cross-supply-agreement
Today, WebMD Health Corp. (NASDAQ: WBMD) announced new features and functionality for its Healthy Target behavior change program that connects seamlessly with Apple’s HealthKit and provides users with powerful new ways to capture, visualize and understand health information from a broad range of biometric devices.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/70402511-web-md-updates-healthy-target-behavior-change-program-apple-healthkit/
BMM, Asia’s only Midnight Marathon, was conceived by Rotary Bangalore IT Corridor (RBITC) and the first edition run was held on 19th May 2007. Since then this event is growing from year to year and today people from more than 20 countries are participating in this event and also the number of runners from 2400 in the Year 2007 has increased to 10,000 runners apart from 45 Corporates participating in the event held in 2013, being the seventh edition run. RBITC’s effort in making BMM as a mega event is laudable as it focuses both on bringing about awareness amongst today's youth of the need to be physically fit and mentally strong and also transforming this as a vehicle for raising funds for various charitable activities, aimed at bringing about a difference in the lives of the underprivileged section of the society. To-day BMM has become the largest fund raising platform for RBITC. Some of the major activities undertaken by them are Adoption of Government Schools, Medical Surgeries, Free Eye Surgeries, Holding Blood Donation Camps, Integrated Village Development, Potable Water Project etc.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7398551-bengaluru-midnight-marathon-2014/
Significant advances toward cures for blood cancer patients, many of which were funded by The Leukemia & Lymphoma Society (LLS) over the past 65 years, are among the dramatic highlights featured in Ken Burns presents CANCER: THE EMPEROR OF ALL MALADIES, a film by Barak Goodman, to air on PBS stations nationwide from March 30-April 1. The documentary series is based on the Pulitzer Prize-winning book by Siddhartha Mukherjee, MD, The Emperor of All Maladies: A Biography of Cancer.
LLS has been a driving force behind treatment breakthroughs for patients with blood cancers, including leukemia, lymphoma and myeloma. As the world’s largest voluntary health agency dedicated to finding cures for blood cancer patients, LLS has invested more than $1billion in research to advance lifesaving treatments and cures.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7409151-lls-cancer-research-pbs-series/
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by blocking BTK, a protein that helps certain cancer cells live and grow.1 IMBRUVICA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cll/
Stranger in the Dark is based on the story arc of a young girl who moves to a small town.
The horror starts when she wakes up one morning to find herself scared as she confronts her greatest fear, the Stranger in the Dark.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the American Diabetes Association today issued a new challenge to the millions of Americans affected by type 2 diabetes as part of the program America’s Diabetes Challenge: Get to Your Goals. In 2015, award-winning artist Tim McGraw, celebrated actress S. Epatha Merkerson and chef Leticia Moreinos Schwartz each shared their personal connection to type 2 diabetes. This year, they’re calling on people to share their stories.
Living with diabetes isn’t easy, and that’s why America’s Diabetes Challenge encourages people with type 2 diabetes to work with their doctor to set and reach their A1C goal. The program will aim to identify the most common challenges patients submit and will offer tips to help address them. The program is also designed to help people learn if they’re at risk of low blood glucose, known as hypoglycemia, and how to help reduce that risk.
To view the multimedia release go to:
http://www.multivu.com/players/English/7785551-merck-americas-diabetes-challenge/
During the Academy of Nutrition and Dietetics 2017 Food & Nutrition Conference & Expo™ in Chicago, scientists reported on a recent study which uncovered that the intake of pistachios reduces the rise in blood sugar and insulin in women diagnosed with gestational diabetes mellitus (GDM)—commonly known as gestational diabetes. The study, “Effects of Pistachio Intake on Postprandial Blood Glucose Response in Pregnant Women,” found when women who were gestational glucose intolerant (GIGT) or who were diagnosed with GDM ate pistachios, they had a significantly lower rise in blood glucose levels compared to eating whole wheat bread that was matched for calories.
To view the multimedia release go to:
https://www.multivu.com/players/English/8162751-american-pistachio-growers-pistachio-health-benefits-women-gestational-diabetes/
ACCU-CHEK Aviva Expert offers people with diabetes a new and easy way to simplify complex calculations to deliver precise insulin dosing advice.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the ACCU-CHEK® Aviva Expert system, the first and only blood glucose meter system with a built-in insulin calculator to be approved by the U.S. Food and Drug Administration (FDA), is now available by prescription. The device represents a significant advancement in blood glucose meter technology for people with diabetes who take multiple daily insulin injections. The meter’s integrated bolus calculator provides easy-to-use and reliable dose recommendations based on automated calculations, eliminating the need for manual dosing calculations and estimations.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7322751-roche-accu-chek-aviva-expert-blood-glucose-meter-now-available/
There is a lot of controversy and debate about whether you need to do a colon cleansing. Some say it is necessary and others say it's a waste of money and can do your body harm. You can imagine who it says it harms. Doctors say it's a waste of time and practitioners that offer a colon cleansing service cleansing say it is not. So who will you believe?
February is American Heart Month, and consumers should be aware that a high-sodium diet can increase their risk of developing high blood pressure. An estimated one in three Americans suffer from high blood pressure, which can increase the risk of developing cardiovascular disease – the leading cause of death in men and women in the United States.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65492-u-s-fda-reduce-sodium-intake-by-using-the-nutrition-facts-label
The Leukemia & Lymphoma Society (LLS) today announced it has committed $28.6 million in new research investment to advance the most promising blood cancer science at leading academic and medical institutions around the world, including Dana-Farber Cancer Institute, Weill Cornell Medical College and MD Anderson Cancer Center. As LLS leads the charge to find cures for cancer patients, this new funding, along with ongoing investment in LLS’s aggressive research agenda, brings LLS’s total commitment to blood cancer research to more than $1 billion. The investment has led to the development of nearly every therapy currently used to treat the blood cancers.
Along with these new research grants, LLS remains committed to collaborating with biotechnology companies through its innovative Therapy Acceleration Program® (TAP), a model pioneered by LLS in the cancer arena in recognition that traditional research approaches weren’t yielding treatments and cures fast enough for patients. LLS commits approximately $13 million a year to its TAP initiatives. As part of the 24 current such collaborations, LLS recently initiated new investments with Kite Pharma and OncoPep.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554852-lls-cancer-research-funding/
